Trevena, Inc.(TRVN)

Sector:

Healthcare

Description:

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Current Price

$1.07

RSI

37.19

Market Capitalization:

82.6M

Beta:

2.245

Volume:

1,083,701

Analyst Target Price:

$ 4.67

Economiic Fair Price:


November 21, 2022
November 09, 2022
Q3
N/A
N/A
N/A
N/A
N/A
22.4M
873000
-0.306
N/A
0.004
-0.524

$ 567.00
-99.98 %
$ 3.1M
9800.00 %
$ 31K
-99.46 %
$ 5.7M
52.85 %
$ 3.8M

$ -50.2M
-134.41 %
$ -21.4M
9.49 %
$ -23.7M
7.35 %
$ -25.5M
65.83 %
$ -74.8M
18.89 %
$ -92.2M

$ -51.6K
99.82 %
$ -29.1M
-16.88 %
$ -24.9M
17.20 %
$ -30M
70.83 %
$ -103M

News

Press Releases

Notable Dates